Učitavanje...
Reduced Dose Ibrutinib Due to Financial Toxicity in CLL
Ibrutinib is the only approved novel agent that is available for the treatment of relapsed-refractory and treatment-naive chronic lymphocytic leukemia patients with deletion 17p or TP53 mutation in India. The cost of ibrutinib is still prohibitive for most Indian CLL patients. We report here for the...
Spremljeno u:
| Izdano u: | Indian J Hematol Blood Transfus |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer India
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6439022/ https://ncbi.nlm.nih.gov/pubmed/30988561 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12288-018-1011-4 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|